Cancer Family
Bone Marrow Neoplasm
CI-CAN-00000093Explore in graph →
Non-malignant1,035 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000093Explore in graph →
Clinical trials
4,615 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05166135 | Latin American Real-world Study in Acute Leukemia(LOYAL) | completed | — | 589 | PfizerINDUSTRY | 4 | Mar 25, 2025 | clinicaltrials |
| NCT03280030 | A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML | completed | Phase 2 | 67 | Novartis PharmaceuticalsINDUSTRY | 6 | Mar 20, 2025 | clinicaltrials |
| NCT02193958 | Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies | completed | Phase 1 / Phase 2 | 55 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | completed | Phase 1 / Phase 2 | 277 | Karyopharm Therapeutics IncINDUSTRY | 5 | Mar 19, 2025 | clinicaltrials |
| NCT03745716 | APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) | completed | Phase 3 | 154 | Aprea TherapeuticsINDUSTRY | 2 | Mar 18, 2025 | clinicaltrials |
| NCT01050036 | Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia | completed | N/A | 20 | Asan Medical CenterOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT01804985 | De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia(DESTINY) | completed | Phase 2 | 174 | University of LiverpoolOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT00719888 | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | completed | Phase 2 | 135 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06865352 | Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 15 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT02834390 | Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 1 | 7 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT02396134 | Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 2 | 61 | City of Hope Medical CenterOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04126681 | A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase | completed | Phase 2 | 144 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06488456 | Psychometric Properties of the Therapy-Related Symptom Checklist-Children | completed | — | 300 | Ege UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT02038777 | A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies | completed | Phase 1 | 48 | PfizerINDUSTRY | 1 | Feb 26, 2025 | clinicaltrials |
| NCT04242849 | IDH1/2 Mutational Analysis in AML Patients: Diagnosis and Follow-up | completed | — | 354 | Josep Carreras Leukaemia Research InstituteOTHER | 0 | Feb 21, 2025 | clinicaltrials |
| NCT03839446 | Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy | completed | Phase 2 | 16 | Robert Redner, MDOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT00390793 | Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. | completed | Phase 2 | 107 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT04372433 | IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML | completed | Phase 1 | 67 | Immune-Onc TherapeuticsINDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05030675 | Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents | completed | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT04281498 | Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation | completed | Phase 2 | 6 | John MascarenhasOTHER | 2 | Feb 4, 2025 | clinicaltrials |
| NCT04803721 | Interplay Between Immune and Metabolic Programs in Myelodysplastic Syndromes(IMET-MDS) | completed | — | 137 | University Hospital, ToulouseOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT03027102 | Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia | completed | Phase 1 | 7 | University Health Network, TorontoOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT06469138 | A Study to Investigate 14C-bemcentinib in Healthy Male Subjects(8479217) | completed | Phase 1 | 6 | BerGenBio ASAINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06790680 | GITMO AML/MDS-Relapse Registry Study | completed | — | 859 | Gruppo Italiano Trapianto di Midollo OsseoOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT03154190 | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer | completed | N/A | 128 | Stanford UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT01261312 | SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) | completed | Phase 1 / Phase 2 | 414 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Jan 23, 2025 | clinicaltrials |
| NCT02997202 | A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) | completed | Phase 3 | 356 | Astellas Pharma Global Development, Inc.INDUSTRY | 16 | Jan 17, 2025 | clinicaltrials |
| NCT03092674 | Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 2 / Phase 3 | 76 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2025 | clinicaltrials |
| NCT02268253 | Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) | completed | Phase 1 / Phase 2 | 82 | Stemline Therapeutics, Inc.INDUSTRY | 2 | Jan 6, 2025 | clinicaltrials |
| NCT03869476 | Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.(BioScoreSMP) | completed | N/A | 133 | University Hospital, AngersOTHER_GOV | 1 | Dec 30, 2024 | clinicaltrials |
| NCT03194685 | Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 97 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT02488408 | A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS | completed | Phase 1 / Phase 2 | 122 | BerGenBio ASAINDUSTRY | 4 | Dec 19, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT00965224 | Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma | completed | Phase 2 | 38 | Zwi BernemanOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT02085408 | Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 3 | 727 | ECOG-ACRIN Cancer Research GroupNETWORK | 3 | Dec 13, 2024 | clinicaltrials |
| NCT02807558 | A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | 155 | Syros PharmaceuticalsINDUSTRY | 2 | Dec 13, 2024 | clinicaltrials |
| NCT00452023 | Pegasys® in Patients With Myeloproliferative Diseases | completed | Phase 2 | 83 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT02014558 | Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 265 | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Dec 3, 2024 | clinicaltrials |
| NCT03730012 | A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 11 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06709235 | Assessing Refractoriness and Infectious Survival Events in AML(ARISE-AML) | completed | — | 280 | Hospices Civils de LyonOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT02927262 | A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission | completed | Phase 2 | 98 | Astellas Pharma Global Development, Inc.INDUSTRY | 21 | Nov 26, 2024 | clinicaltrials |
| NCT04079296 | A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS) | completed | Phase 1 / Phase 2 | 43 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Nov 26, 2024 | clinicaltrials |
| NCT01266083 | WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) | completed | Phase 2 | 22 | Sellas Life Sciences GroupINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT02561455 | Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial | completed | Phase 1 / Phase 2 | 9 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03761914 | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | completed | Phase 1 / Phase 2 | 26 | Sellas Life Sciences GroupINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06692803 | Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy(ABL-2022-03) | completed | — | 2,043 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05659992 | Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06002490 | A Study to Evaluate P1101 in Japanese PV Patients | completed | Phase 3 | 21 | PharmaEssentia Japan K.K.INDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT04253314 | A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation(INNOVATE) | completed | — | 51 | AbbVieINDUSTRY | 1 | Nov 7, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 25, 2025source: clinicaltrials